Nitto Denko Avecia Inc. and Nitto Denko Avecia Pharma Services (Nitto Avecia), leading companies in the development and manufacturing of oligonucleotides for the therapeutic market, have announced the appointment of Tammy Cooper as the President of Nitto Avecia, effective from June 21, 2024. Cooper, currently serving as the Vice President of Business Development and Project Management at Nitto Avecia, will report to Yoshihiko Terada, who will assume the role of Chairman of the Board of Nitto Avecia.
Cooper brings a wealth of experience in the pharmaceutical industry, starting her career as a chemist specializing in the formulation of small molecules. Over her 19-year tenure at Nitto Avecia, she has held various roles in marketing, business development, and project management, progressively taking on more responsibilities. Most recently, she served as the Vice President of Business Development and played a pivotal role in Nitto Avecia’s rapid growth phase.
Expressing her honor at becoming the first female President of Nitto Avecia, Cooper highlights the limitless opportunities that lie ahead for the company. She emphasizes their commitment to innovation, aiming to elevate the development and manufacturing of oligonucleotides to new levels of success.
Terada, who has been with Nitto Denko for nine years, has prior experience in the pharmaceutical industry and consulting. He served as Chief of Staff at Nitto Avecia and as Corporate Vice President of Nitto Denko. Terada expresses his excitement at the positive prospects for the oligonucleotide market and the significant opportunities that Nitto Avecia and Nitto Avecia Pharma Services have in collaborating with customers on life-changing and life-saving medications.
Both Terada and Cooper will operate from the Nitto Avecia headquarters in Milford, MA.
Nitto Denko Avecia Inc. is a recognized leader in the development and manufacturing of oligonucleotide therapeutics, with facilities in Milford, MA, and Cincinnati, OH, along with Nitto Avecia Pharma Services in Irvine, CA, catering to preclinical through commercial requirements. The company has manufactured over 1,200 oligonucleotide sequences and has developed an extensive late-stage portfolio. It is the first CDMO to offer a comprehensive end-to-end oligonucleotide solution.
Nitto Denko Corporation, founded in 1918, is Japan’s leading material manufacturer, offering over 13,500 diverse industrial products for more than 70 business sectors, including electronics, automobiles, ecology, and life sciences. The company is committed to customer-oriented innovation and strives to become an indispensable top ESG company that continuously astonishes and inspires.
For more information, please contact:
Keri Dufault, Senior Director, Business Development and Marketing, Nitto Denko Avecia Inc. [email protected]
While the article provides information about Tammy Cooper’s appointment as President of Nitto Denko Avecia, it lacks additional details about current market trends and forecasts in the oligonucleotide therapeutics industry. Here are some facts to supplement the discussion:
1. Market Trends: The demand for oligonucleotide therapeutics has been steadily increasing due to their potential in treating genetic disorders, cancer, and other diseases. The market is driven by ongoing advancements in nucleic acid technologies, improved delivery methods, and better understanding of oligonucleotide mechanisms.
2. Forecast: The oligonucleotide therapeutics market is expected to witness substantial growth in the coming years. According to a report by Grand View Research, the global market size is projected to reach $8.2 billion by 2027, with a compound annual growth rate (CAGR) of 12.8% from 2020 to 2027. Factors such as increasing prevalence of genetic disorders and growing investments in research and development contribute to this optimistic outlook.
3. Key Challenges and Controversies: The development and manufacturing of oligonucleotide therapeutics face challenges related to efficient delivery into target cells and tissues. Achieving optimal target engagement, minimizing off-target effects, and ensuring adequate stability of the oligonucleotide molecule are ongoing challenges. Additionally, there have been debates surrounding the high costs of oligonucleotide therapies and the accessibility of these treatments to patients.
Advantages of Tammy Cooper’s Appointment:
– With her 19-year tenure at Nitto Avecia and experience in various roles, Cooper brings a deep understanding of the company’s operations and industry dynamics.
– Her expertise in business development and project management positions Nitto Avecia well for future growth and strategic collaborations.
– Cooper’s background as a chemist specializing in small molecule formulation brings a unique perspective to the development of oligonucleotide therapeutics.
Disadvantages of Tammy Cooper’s Appointment:
– One potential disadvantage could be a lack of experience in executive leadership roles. While Cooper has held various positions within Nitto Avecia, her transition to the role of President may require further development of leadership skills.
– Another disadvantage might be the potential challenge of managing the company’s diverse operations across different locations effectively.
For more information about Nitto Denko Avecia and its activities, please visit their official website: Nitto Denko Avecia.